Business context and reporting period
Filing identity: The supplied filing is Stellar Biotechnologies, Inc.’s Form 10-K for the fiscal year ended September 30, 2018—not an Edesa Biotech, Inc. filing. The period is an annual fiscal year, not a standalone 2018 fourth-quarter report. The company develops and supplies keyhole limpet hemocyanin (KLH) for research and third-party immunotherapy programs. Its KLH had not yet been used in a marketed drug.
Financial performance and position
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Revenue | $211,849 | $228,287 |
| Operating expenses | $5.29 million | $5.45 million |
| Operating loss | $5.08 million | $5.22 million |
| Net loss | $5.04 million | $5.03 million |
| Net loss per share | $1.76 | $3.44 |
| Cash used in operations | $4.62 million | $4.70 million |
| Capital expenditures | $382,810 | $302,733 |
Product sales rose to $211,849 from $178,287, while contract-services revenue fell to zero from $50,000; total revenue therefore declined about 7%. The prior-year services revenue related to a technology transfer. Research and development expense increased to $2.09 million from $1.97 million; general and administrative expense decreased to $2.76 million from $2.94 million. The filing does not report a gross-margin percentage.
At September 30, 2018, cash and cash equivalents were $4.23 million, short-term U.S. Treasury investments were $6.08 million, working capital was approximately $10.2 million, and shareholders’ equity was $11.29 million. Current liabilities were $493,385; the balance sheet reports no debt. The company raised net financing cash of $8.77 million through an offering and warrant exercises. Common shares outstanding increased from 1,502,870 to 5,330,715, reflecting financing, warrant exercises, and the one-for-seven reverse split on May 4, 2018.
Changes, outlook, and risks
Management said available cash and investments plus product sales were expected to fund operations for at least 12 months after year-end. It expected further losses and reserved the option to seek debt or equity financing. Management may adjust spending, staffing, inventory, and capital investment in response to customer clinical-trial progress and market conditions.
Capital spending supported aquaculture-site improvements and manufacturing capacity; the company described modular expansion plans but tied future investment to customer milestones and market conditions. Research and development focused on aquaculture and improving KLH manufacturing scalability and throughput.
- Revenue depends on third-party clinical development, trial outcomes, regulatory approval, and eventual market adoption; customers fund and manage their own drug development.
- Revenue is concentrated: two customers represented 59% of FY 2018 revenue, and two represented 79% in FY 2017. Neovacs and Zoetis accounted for 36% and 23% of FY 2018 revenue, respectively.
- Operations and facilities are concentrated in coastal Port Hueneme, California, with no active backup site. Manufacturing also relies on third-party contractors for certain processing and testing.
- The 30%-owned Neostell joint venture faced a December 31, 2018 milestone deadline that could lead to dissolution unless the parties agreed otherwise or one party bought out the other. The filing says discussions were ongoing; the ultimate outcome is not provided.
- Other material risks include limited KLH sales, competition, manufacturing scale-up and GMP compliance, limpet supply, foreign-exchange exposure, intellectual-property protection, and potential dilution from future financing. The company reported no material legal proceedings outside the ordinary course and no off-balance-sheet arrangements.
Disclosure controls and internal control over financial reporting were assessed by management as effective at September 30, 2018. The external auditor audited the financial statements but did not attest to internal-control effectiveness.
Investor facts to verify
- Confirm the issuer and filing: this is Stellar Biotechnologies, Inc., not Edesa Biotech, Inc.
- Check subsequent cash burn, financing needs, and the company’s liquidity runway against the reported $10.3 million in cash and short-term investments.
- Verify the outcome of Neostell’s December 31, 2018 milestone deadline and any related funding or buyout obligations.
- Track customer clinical milestones, contract renewals, customer concentration, and whether any KLH-based customer product advances toward regulatory filing or commercialization.
- Assess share dilution and warrant overhang: 4,093,960 warrants were outstanding at September 30, 2018, alongside the increased share count from 2018 financing and exercises.